文献速递前列腺癌

高危前列腺癌雄激素剥夺治疗时长:随机III期试验

Duration of Androgen Deprivation Therapy in High-risk Prostate Cancer: A Randomized Phase III Trial.
PubMed 文献 · Eur Urol · 2018-07-03

这项 superiority 随机试验比较盆腔和前列腺放疗联合36个月或18个月ADT治疗630例局限高危前列腺癌患者,中位随访9.4年,36个月组5年OS为91%、18个月组为86%(p=0.07),QoL分析有6个量表和13个条目显著 favoring 18个月ADT。结论支持36个月不优于18个月,ADT联合RT可考虑减至18个月。

要点

  • 局限高危前列腺癌放疗联合ADT,36个月不优于18个月。
  • 两组5年OS无显著差异(91% vs 86%,p=0.07)。
  • 18个月ADT组生活质量更优,部分差异具临床相关性。

核心结论

  • 在局限高危前列腺癌中,36个月ADT不优于18个月ADT。
  • ADT联合放疗在选定患者中可减至18个月而不影响生存或生活质量。
  • 18个月ADT似乎是高危前列腺癌的有效选择。

研究设计与样本

  • superiority 随机III期试验,2000年10月至2008年1月随机630例高危前列腺癌患者。
  • 长臂310例接受盆腔和前列腺放疗联合36个月ADT,短臂320例接受相同放疗联合18个月ADT。
  • 主要终点为总生存(OS)和生活质量(QoL),OS采用Cox回归模型比较,QoL采用混合线性模型分析。

主要发现

  • 中位随访9.4年,共290例死亡(长臂147例 vs 短臂143例)。
  • 5年OS率(95%CI)长臂为91%(88-95%),短臂为86%(83-90%),p=0.07。
  • QoL分析显示6个量表和13个条目存在显著差异(p<0.001),均 favoring 18个月ADT,其中2个条目平均分差异≥10分具临床相关性。

临床怎么用

  • 对局限高危前列腺癌患者,放疗联合ADT的疗程可考虑从36个月缩短至18个月。
  • 缩短ADT疗程可能改善生活质量而不损害生存。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Long-term androgen deprivation therapy (ADT) combined with radiotherapy (RT) is a standard treatment for patients with localized high-risk prostate cancer (HRPC). However, the optimal duration of ADT is not yet defined. OBJECTIVE: The aim of this superiority randomized trial was to compare outcomes of RT combined with either 36 or 18 mo of ADT. DESIGN, SETTING AND PARTICIPANTS: From October 2000 to January 2008, 630 patients with HRPC were randomized, 310 to pelvic and prostate RT combined with 36 mo (long arm) and 320 to the same RT with 18 mo (short arm) of ADT. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Overall survival (OS) and quality of life (QoL) were primary end points. OS rates were compared with Cox Regression model and QoL data were analyzed through mixed linear model. RESULTS AND LIMITATIONS: With a median follow-up of 9.4 yr, 290 patients had died (147 long arm vs 143 short arm). The 5-yr OS rates (95% confidence interval) were 91% for long arm (88-95%) and 86% for short arm (83-90%), p=0.07. QoL analysis showed a significant difference (p<0.001) in six scales and 13 items favoring 18 mo ADT with two of them presenting a clinically relevant difference in mean scores of ≥10 points. CONCLUSIONS: In localized HRPC, our results support that 36 mo is not superior to 18 mo of ADT. ADT combined with RT can potentially be reduced to 18 mo in selected men without compromising survival or QoL. Thus, 18 mo of ADT appears to represent a valid option in HRPC. PATIENT SUMMARY: In this study, we report outcomes from high-risk prostate cancer patients treated with radiotherapy and either 36 or 18 mo of androgen deprivation therapy. There was no difference in survival between the two groups, with the 18-mo group experiencing a better quality of life.

来源:Eur Urol,查看原文。版权归原作者所有。

引用

  1. Nabid A, Carrier N, Martin AG, et al. Duration of Androgen Deprivation Therapy in High-risk Prostate Cancer: A Randomized Phase III Trial. Eur Urol. 2018. PMID: 29980331. doi:10.1016/j.eururo.2018.06.018

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。